Ichiro Oikawa
Oita, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Water intake during drinking does not alleviate hangover symptoms.
Journal: Frontiers in pharmacology
Published: April 10, 2026
Utility of Modeling and Simulations in Drug Development: Contrasting Japan, US and UK Descriptions of PBPK Modeling from Package Inserts.
Journal: The AAPS journal
Published: November 26, 2025
Fixed Versus Lottery Incentives for Promoting Engagement With a Cadence-Based Smartphone App: Randomized Crossover Trial.
Journal: JMIR formative research
Published: October 22, 2025
Correction: Assessing Immunogenicity in Drug Reviews and Prescribing Information in Japan.
Journal: The AAPS journal
Published: February 12, 2025
Assessing Immunogenicity in Drug Reviews and Prescribing Information in Japan.
Journal: The AAPS journal
Published: July 02, 2024
Cadence-Based Pedometer App With Financial Incentives to Enhance Moderate-to-Vigorous Physical Activity: Development and Single-Arm Feasibility Study.
Journal: JMIR formative research
Published: January 15, 2024
Evaluation of the potential drug-drug interactions of carotegrast methyl with midazolam, prednisolone or atorvastatin in healthy adults.
Journal: British journal of clinical pharmacology
Published: September 28, 2023
Effects of rifampicin on the pharmacokinetics and safety of carotegrast methyl in healthy subjects: A randomized 2 × 2 crossover study.
Journal: British journal of clinical pharmacology
Published: September 28, 2023
Appraisal of ICH E14/S7B Q&As adopted in February 2022 using thorough QT/QTc study data for α4-integrin antagonist carotegrast methyl in Japanese healthy subjects.
Journal: Journal of pharmacological sciences
Published: July 19, 2022
Food Effect on a Single High Dose of Carotegrast Methyl, an Oral Antagonist of α4-Integrin, in Healthy Male Subjects: A Randomised, Placebo-Controlled, Double-Blind Study.
Journal: Clinical drug investigation
Published: January 23, 2020
AJM300, a novel oral antagonist of α4-integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects.
Journal: British journal of clinical pharmacology
Published: June 10, 2019
Last Updated: 09/26/2026